John Rodgers Braddock, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4000 Kruse Way Pl, Building 2, Suite 160, Lake Oswego, OR 97035 Phone: 503-635-1960 Fax: 503-635-8354 |
Dr. George M Douglass Jr., MD Emergency Medicine - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 17355 Boones Ferry Rd, Suite C, Lake Oswego, OR 97035 Phone: 503-344-6445 Fax: 503-344-6852 |
Dr. John S Hoppock, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5519 Bay Creek Dr, Lake Oswego, OR 97035 Phone: 503-750-1946 |
Dr. Harold Thomas, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 734 Carrera Ln, Lake Oswego, OR 97034 Phone: 503-636-9234 |
Dr. Michael Barmache, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 17437 Boones Ferry Rd, Suite 100, Lake Oswego, OR 97035 Phone: 503-305-6262 |
News Archive
Authentidate Holding Corp., a worldwide provider of secure Health Information Exchange, workflow management services and telehealth solutions, today announced that it has completed the previously announced sale of certain non-core assets to Star Advisors, LLC, acting on behalf of the principals of Astria Solutions Group, LLC, for approximately $2.4 million. The assets sold by the company include the company's land and building in Schenectady, NY, which was leased by Astria.
More than 15 million Americans live within a one-mile radius of unconventional oil and gas operations. UOGs combine directional drilling and hydraulic fracturing, or "fracking," to release natural gas from underground rock.
The International Society for Heart and Lung Transplantation (ISHLT) today announces new guidelines to standardize care for heart transplant patients worldwide. The guidelines demonstrate a united effort to decrease complications, improve outcomes and increase patient survival rates among heart transplant recipients. The guidelines will be presented during today's symposium The ISHLT Guidelines for Heart Transplant Recipients: Towards an International Consensus at the ISHLT 30th Annual Meeting and Scientific Sessions at the Hilton Chicago.
Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of AvastinĀ® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.
› Verified 7 days ago